Empyrean Capital Partners, LP Atai Life Sciences N.V. Transaction History
Empyrean Capital Partners, LP
- $2.01 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding ATAI
# of Institutions
87Shares Held
12.4MCall Options Held
77.8KPut Options Held
50.3K-
Morgan Stanley New York, NY3.04MShares$5.13 Million0.0% of portfolio
-
Walleye Capital LLC Plymouth, MN2.26MShares$3.83 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$2.21 Million0.0% of portfolio
-
Brown University719KShares$1.21 Million0.36% of portfolio
-
Round Table Services, LLC704KShares$1.19 Million0.46% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $280M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...